MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a study for patients with previously-treated advanced non-small cell lung cancer
(NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to
standard treatment with gemcitabine. The study will also try to identify the best dose of
MK-3475 to give in combination with gemcitabine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Providence Health & Services
Collaborators:
Merck Sharp & Dohme Corp. Providence Cancer Center, Earle A. Chiles Research Institute